Press Releases

Date Title
Toggle Summary Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results
Management to host webcast and conference call today at 4:30 p.m. EDT LA JOLLA, Calif. , March 14, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , (NASDAQ:KURA) a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported fourth quarter
Toggle Summary Kura Oncology to Report Fourth Quarter and Full Year 2016 Financial Results
LA JOLLA, Calif. , March 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2016 financial results after the close
Toggle Summary Kura Oncology Reports Updated Clinical Activity Data in Ongoing Phase 2 Trial for Tipifarnib
LA JOLLA, Calif. , March 06, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced updated results from the ongoing, Phase 2 trial of tipifarnib, a selective inhibitor of
Toggle Summary Kura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017
LA JOLLA, Calif. , Feb. 27, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced an oral presentation for its lead product candidate, tipifarnib, at the 15 th International Congress on Targeted Anticancer Therapies (TAT 2017),
Toggle Summary Kura Oncology to Participate in Three Upcoming Investor Conferences
LA JOLLA, Calif. , Feb. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company at three upcoming investor
Toggle Summary Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
LA JOLLA, Calif. , Jan. 17, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase 2 clinical trial of tipifarnib in patients with chronic myelomonocytic leukemia (CMML).
Toggle Summary Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 and Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program
LA JOLLA, Calif. , Jan. 04, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ( FDA ) accepted the company’s Investigational New Drug (IND) application to begin Phase 1 clinical testing
Toggle Summary Kura Oncology Appoints Steven Stein, M.D. to Board of Directors
LA JOLLA, Calif. , Jan. 03, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced the appointment of Steven H. Stein , M.D., to its board of directors. Dr. Stein currently serves as Executive Vice President and Chief Medical Officer
Toggle Summary Kura Oncology Presents Preclinical Data on KO-947 and Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
LA JOLLA, Calif. , Dec. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today presented preclinical data highlighting the identification and characterization of KO-947, its development candidate targeting ERK1/2 kinases.
Toggle Summary Kura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
LA JOLLA, Calif. , Nov. 15, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company developing precision medicines for cancer, today announced it will be presenting two posters at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer